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Supplementary files 1. Relations between drug interactions, side effects and indications
We examined whether the number of indications and side effects of each drug correlated with its number of interactors. We retrieved drug indications and side effects from several sources. Specifically, drug indications were assembled from multiple sources including DrugBank (Wishart et al, 2008) , FDA drug labels in the DailyMed website (http://dailymed.nlm.nih.gov) and from http://drugs.com exploiting the MetaMap tool (Aronson, 2001) to parse textual indications in the same manner described in (Gottlieb et al, 2011) and drug side effects downloaded from SIDER (Kuhn et al, 2010) . We proceeded to compute Spearman ranked correlations between the number of drug properties associated with each of 279 drugs involved in all types of DDIs (CRDs, PCRDs and NCRDs) and having indication and side effect information ( Figure S2 ). The number of CRDs are not correlated with NCRDs (ρ=-0.11, p=0.06), while the number of PCRDs of a drug are positively correlated with the number of NCRDs (ρ =0.63, p=0) and uncorrelated with CRDs (ρ=0.05). An interesting finding is that the number of diseases a drug is indicated for is moderately correlated with NCRDs (ρ= 0.34, p=8e -9 ), while uncorrelated with CRDS or PCRDs (-0.003 and 0.09, respectively). We checked whether the correlation between indications and NCRDs may be attributed to drugs that target multiple proteins or alternatively target "hub" proteins (i.e. proteins targeted by multiple drugs). These drugs may show tendency to treat multiple diseases and may be more prone to be involved in NCRDs. In order to test this hypothesis, we retrieved drug targets from DrugBank (Wishart et al, 2008) , DCDB (Liu et al, 2010) , Matador (Gunther et al, 2008) and KEGG DRUG (Kanehisa et al, 2010) and computed ranked partial correlations, controlling for the numbers and degrees of drug targets. The partial correlation, however, was only slightly smaller (ρ= 0.32, p=7e -8 ), ruling out this explanation. Thus another possible explanation is that drugs treating multiple diseases may affect central pathways, causing more NCRDs. Finally, side effects have low correlation with CRDs, NCRDs or PCRDs (0.15, p= 0.04, 0.13, p=0.01 and 0.19, p=0.002, respectively) .
Analyzing the correlations between our predicted DDIs and known DDIs, we verified that the number of predicted interactors for each drug (excluding predictions which are known DDIs, e.g. known PCRDs) is positively correlated with the number of the known interactors (Spearman ranked correlation between known CRDs and predicted CRDs, ρ =0.77, p=5e -50 and between known NCRDs and predicted NCRDs ρ=0.59, p=0), meaning that "promiscuous" drugs, i.e. drugs interacting with multiple drugs retain this property. The correlations between both predicted CRDs and predicted NCRDs to known interactions from other types (i.e., predicted CRDs vs. known NCRDs or known PCRDs and predicted NCRDs vs. known CRDs and PCRDs) remained low (Spearman ranked correlations ranged between -0.17 and 0.14, p-values significant only for predicted NCRDs vs. known CRDs and predicted CRDs vs. PCRDs). Pearson correlations displayed the same trend: correlation between known CRDs and predicted CRDs, ρ =0.79, p=2e -54 and between known NCRDs and predicted NCRDs ρ=0.48, p=0; correlations between both predicted CRDs and predicted NCRDs to known interactions from other types remained low -between -0.17 and 0.06, p-values significant only for predicted NCRDs vs. known CRDs. The trend portrayed in the previous paragraph was retained for the predicted DDIs, where the number of indications for a drug is moderately correlated with predicted NCRDs (ρ=0.23, p=2e -6 ), while not correlated with predicted CRDs. Similarly, side effects have low correlation with predicted CRDs or NCRDs.
We further examined the fluctuations in the number of drug interactions, indications and side effects of 249 approved drugs over a period of 50 years (Methods), depicted in Figure S3 . Interestingly, we found that the average number of indications and NCRD interactors per drug is decreasing in recently approved drugs (Spearman correlation between per-drug number of indications and interactors, ρ =-0.8, p=0.008 and ρ =-0.7, p=0.03, respectively), whereas side effects are higher in recently approved drugs (Spearman correlation, ρ =0.73, p=0.02). Performing the same analysis for predicted CRDs and NCRDs, we find that the number of CRD predictions per drug is higher in recently approved drugs (Spearman correlation, ρ =0.7, p=0.03) whereas NCRD predictions show no statistically significant trend ( Figure S4 ).
Validation of predicted DDIs
In order to validate our predictions, we initially trained on the smaller set of DrugBank DDIs, including 1,162 interactions spanning 251 drugs and 2,027 interactions spanning 499 drugs for CRDs and NCRDs, respectively. We used the larger set of Drugs.com interactions (excluding interactions appearing in DrugBank) for validation only. We selected a cutoff for the ranked list of predictions according to the best F1-measure obtained from the cross-validation (obtaining similar AUC scores to the cross validation on the full set, Table S4 ), resulting in 15,782 predicted CRDs and 28,873 predicted NCRDs. 10% of the CRD predictions and 25% of the NCRD predictions significantly overlapped the corresponding Drugs.com known DDIs (p=0 in both). Additionally, Drugs.com PCRDs were also highly enriched within both CRD and NCRD predictions (15%, p=e -311 and 16%, p=0, respectively). Interestingly, 13% of the CRD predictions were known Drugs.com NCRDs (p=7e -25 ) and 5% of the NCRD predictions were known Drugs.com CRDs (p=2e -38 ), suggesting that some DDIs may result from combination of CYP-based and pharmacodynamic mechanisms (for example, the known interaction between Disulfiram and Isoniazid is hypothesized to occur due to sharing of CYP 2E1 and the mutual interference with butanoate metabolism (Brouwers et al, 2011) ). The pvalues obtained for different cutoffs are plotted in Figure S5 .
Considering our full set of predictions (training on DrugBank and Drugs.com datasets), they significantly overlapped known PCRDs (12% of predicted CRDs, p=5e -313 and 28% of predicted NCRDs, p=0). The overlap of DDIs of the opposite type (i.e. known NCRDs appearing in CRD predictions and vice-versa) consisted of 5% CRDs in predicted NCRDs (p=5e -156 ) while statistically insignificant portion of 8% NCRDs in predicted CRDs.
We validated these NCRD predictions based on the assumption they tend to occur among drugs affecting the same tissues. Tissue intersection of drugs can be manifested either by (i) treatment of diseases affecting the same tissues or (ii) targeting genes expressed in the same tissues. For the disease-related validation, we used literature-based disease-tissue associations of Lage et al.(2008) (Lage et al, 2008 ) and a set of drugdisease associations extracted from various databases following the method of (Gottlieb et al, 2011) to associate a drug with a set of tissues affected by diseases the drug is treating. Lage et al. scored disease-tissue associations according to co-mentioning of diseases and tissues across PubMed (Korbel et al, 2005) . We used the score cutoff of 8% suggested by Lage et al. (attaining disease-tissue precision >80%) in order to determine an association between a disease and a tissue. Thus, a drug was associated with a tissue if at least one of its indicated diseases were associated with that tissue. Forming a tissuebased drug-drug similarity measure, we initially verified that drugs interacting via known NCRDs are significantly more similar to each other based on shared tissues than noninteracting pairs of drugs, supporting our assumption (Wilcoxon ranked sum test, p=3e -81 ). Since the ATC similarity measure contains information on the tissues the drugs operate in, we produced an additional set of predictions, excluding the ATC similarity measure, in order to avoid possible bias resulting from tissue similarity between our predicted NCRDs and the gold standard NCRDs. After verification that the exclusion of the ATC similarity measure did not affect significantly the classification performance (Table S4 ), we indeed find that our predictions (excluding known DDIs, i.e. PCRDs), are also significantly similar in terms of mutual tissues (p=2e -34 ). As a sanity check, no randomly shuffled set of the predictions obtained statistical significance. A similar validation to the disease-related tissue validation was performed using tissue-specific expression of drug targets (see Section 1 for sources). We constructed a drug-tissue association matrix based on the tissue-specific gene expression downloaded from Su et al. (Su et al, 2004) of the drug targets. A drug was declared to affect a tissue if at least one of its targets was expressed in that tissue (expression level>200 as suggested by (Su et al, 2004) ). We next formed a tissue-based drug-drug similarity measure based on the Jaccard coefficient between the tissue profiles of pairs of drugs. We initially verified that drugs interacting via known NCRDs tend to have their targets expressed in the same tissues more than non-interacting drug pairs (Wilcoxon ranked sum test, p=7e -45 ).
Excluding target-based similarity measures to avoid possible bias emerging from targetbased similarity between the gold standard and the predictions (verifying that the classification performance remained high, Table S4 ), our predictions were found to significantly share the same targets (Wilcoxon ranked sum test, p=7e -41 ). We note that we do not expect a-priori that CRDs will exhibit the same trend, since these interactions prevalently occur in the liver, renal and intestine tissues (Lohr et al, 1998; Tachibana et al, 2010) . However, known CRDs do show significant co-occurrence in tissues with regard to diseases (p=e -81 ) and with regard to genes (p=0.009). In comparison, predicted CRDs show significant co-occurrence in tissues with regard to genes only (p=3e-21 ) and, importantly, these levels are lower than those observed for predicted NCRDs.
A final NCRD validation assumes that NCRDs affect similar or cross-talking mechanisms of actions, thus treating disease pairs that may also be affected by similar or cross-talking mechanism, contributing to co-morbidity of such pairs. We used drug indications (see Section 1) to form disease-disease associations between pairs of diseases treated by interacting drugs. We next checked for enrichment of the co-morbidity disease pairs, downloaded from (Park et al, 2009 ) in these pairs. As anticipated, NCRD-related disease pairs are indeed enriched with co-morbid diseases (hypergeometric test, p=e -12 ) while CRD-related diseases are not. We found both predicted NCRDs and CRDs (excluding known DDIs) to be enriched (p=4e -17 and p=0.003, respectively), where again CRD enrichment levels were lower than those observed for predicted NCRDs.
Comparison to naïve prediction methods
We wished to compare INDI to a layman approach. To this end, we devised the following naïve method: predict an interaction between a pair of drugs based solely on the similarity between them, where the similarity measure is one of the seven similarity measures used in our algorithm. This naïve approach proved to be a poor predictor for all similarity measures, resulting in AUCs <0.6 for both the CRDs and NCRDs sets. Not surprisingly, the highest AUC was obtained using chemical similarity measure in the CRDs case, while the similarity in drug targets GO annotations performed best for NCRDs ( Figure S6 ). Figure S7 displays the Receiver-Operating Characteristic (ROC) curves of INDI and the naïve method.
Novel interactions between ATC classes
We identified novel CRD and NCRD -based interactions between drug classes identified by the third level ATC classification. We identify that these novel inter-class interactions extend known interactions from other drug classes. Specifically, we indentified a CYP3A4 based CRDs between ATC classes "Anti-estrogens" and "Enzyme inhibitors" (included in class L02B) and glucocorticoids (A07E or R03B), extending similar interactions between the glucocorticoid drug Dexamethosone (which do not belong to either A07E or R03B) and members of this class (e.g. Tamoxifen, Toremifene or Aminogluthetimide). Additionally, there are significant number of NCRDs between different classes of "Adrenergic and dopaminergic agents" (C01C, N04B) and between C01C and "Sympathomimetics, labour repressants" and "Prolactin inhibitors" subclasses (part of G02C class). Some of these interactions are trivial, including additive dopamine agonists (e.g. interactions of Cabergoline, Bromocriptine or Lisuride with Dopamine) or destructive dopamine agonist -antagonist combinations (e.g. Midodrine and Bromocriptine). Other interactions may involve (according to Drugs.com) additive or synergistic increases in blood pressure and/or ischemic response, occurring between ergot alkaloids (e.g. Bromocriptine or Lisuride) and peripheral or central vasoconstrictors (e.g.
Mephentermine, Methoxamine, Midodrine or Phenylephrine). Last, we identified novel interactions between opioids/opiates (N02A or R05D) and various antibiotics (S01A), including quinilones and the macrolid Erythromycin. This inter-class interaction may be associated with one of two potential causes: (i) Certain quinilones and macrolides can potentially produce an additive effect of prolonging QT interval (Ball, 2000; Iannini, 2002; Noel et al, 2003a) when administered with certain opioids (e.g. the QT interval prolonging methadone (Wedam et al, 2007) was predicted to interacts with QT interval prolonging fluoroquinolones (Noel et al, 2003b; Rubinstein and Camm, 2002) ); or (ii) additive effect of hepatotoxicity, i.e. certain opioids are hepatotoxic (Gomez-Lechon et al, 1987 ) (e.g. Buprenorphine (Berson et al, 2001; Hervé et al, 2004) or Oxycodone (Ho et al, 2008) in our predictions) and are predicted to interact with certain hepatotoxic antiobiotics (e.g. Moxifloxacin (Verma et al, 2009) or Erythromycin (Braun, 1969; Tolman et al, 1974) ). Since the levels of either QT interval prolongation or hepatotoxicity vary between opioid and antibiotic class members (e.g. Buprenorphine is associated with less QTc prolongation than Methadone (Wedam et al, 2007) ), it is thus essential to select the combinations that produce milder effect.
Validating predicted DDI recommendations and related CYPs
We predicted recommendations for the predicted DDIs. In order to validate these predictions, we exploited the fact that 21% of the predicted CRDs are known NCRDs or PCRDs and 33% of the predicted NCRDs are known CRDs or PCRDs. We thus used the recommendations of these known DDIs as means for validations. While we trained on recommendations provided for NCRDs and validated against CRD and PCRD recommendations and vice-versa for CRDs, it is notable that all of our predicted recommendation types were statistically significant (Table S5 ). We note that the frequency of each recommendation type in our prediction set (Table 2) , is highly correlated with the frequency of each recommendation type in the known DDIs (Pearson ρ>0.99, p=9e -4 ). We further predicted the adjust dosage sub-categories (decrease, increase, limit dosage and adjust dosage interval). The increase dosage interval is provided by Drugs.com, while the other three sub-categories were retrieved by keywordassisted manual curation (e.g. lower/reduce/decrease dosage, increase dosage, "maximal dosage" or "dosage should not exceed"). We did not predict the "adjust dosage interval" for CRDs and the "limit dosage" for NCRDs due to the rarity of these sub-classes in the training set (3 and 2 such recommendations, respectively). The number of known PCRDs belonging to one of these sub-categories overlapping our predicted CRDs and NCRDs was too low to employ the same validation scheme (20 and 36, respectively, mostly of the "decrease dosage" sub-category). We thus randomly divided the known CRDs and NCRDs into two halves, producing DDI predictions by training on one half and validating against the other (Table S5 ). We note that on the small set of known PCRDs belonging to one of these sub-categories overlapping our predicted CRDs and NCRDs, we made only two classification mistakes: the recommendation for Pravastatin or Rosuvastatin is to limit the dosage when used in combination with Cyclosporine, while we predicted a decrease of dosage for these two interactions. No misclassifications were made for NCRDs.
Using the same methodology, we predicted which CYP enzymes may be the cause of the predicted CRDs. We applied similar prediction procedure as in the recommendation scenario, the difference being that a CRD may be caused by more than one CYP. On a 10-fold cross validation, we find that all seven CYPs obtain high AUC scores (Table S6 ). Overall, we were able to predict related CYPs for 99% of the CRD predictions (including predicted CRDs involving novel drugs), 18% of which have more than one CYP (vs. 14% of the known CRDs). In order to further validate our predictions, we predicted CYPs only for CRDs that were predicted using the DrugBank training set and validated against known CRDs from Drugs.com (Table S6 ). Since known Drugs.com CRDs caused by either CYP 2C8 or 2B6 appear in negligible amounts in our DrugBanktrained predictions (14 and 3 for the 2C8 and 2B6 enzymes, respectively), we used the same scheme as in the adjust dosage sub-category validation scheme -dividing the known CRDs into two halves, training on one half and validating against the other. The p-values obtained for the other CYPs under this validation scheme remained similar.
Predicted DDIs for novel drugs in ADRs
We examined the prevalence of our predictions in ADRs extracted from the US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). We considered drug pairs for which the number of ADRs is significantly higher than would be expected by chance, resulting in 1,988 drug pairs involving drugs included in our CRD and NCRD sets (147 of which contain novel drugs). We found that 6% of these drug pairs are known CRDs (p=4e -27 ), 15% are known NCRDs (p=e -25 ) and 20% known PCRDs (p=e -131 ).
Additionally, 4% of the drug pairs are novel predicted CRDs (p=0.004) and 8% are predicted NCRDs (p=3e -19 ). Moreover, significant 3% (2% known NCRDs, p=3e -10 and 1% predicted NCRDs, p=7e -9 ) of these drug pairs are considered NCRDs with severe recommendations and an additional 1%, severe CRDs (0.8% known, p=5e -6 and only 0.1% predicted, statistically insignificant).
Tolterodine and Ergonovine specific example
We highlight a specific example of a predicted CRD between Tolterodine, an antimuscarinic drug used to treat urinary incontinence, and Ergonovine, an ergot alkaloid with uterine and vascular smooth muscle contractile properties. We further predicted that this interaction involves CYP3A4 and CYP2D6 and recommended to adjust dosage upon administration. Indeed, a similar recommendation was provided by Vij et al.(2009) , stating that since Tolterodine is metabolized by CYP3A4, dose should be halved in patients receiving CYP3A4 inhibitors (Vij et al, 2009) , where Ergonovine is indeed such an inhibitor (Moubarak et al, 2003) . Tolterodine is also a known substrate of CYP2D6 (Brynne et al, 1999) . As specified for multiple Tolterodine CYP3A4-related interactions (84 such interactions downloaded from Drugs.com, e.g. Ergotamine), although the interaction results from CYP3A4, the interaction effect may be greater in patients who are poor metabolizers of CYP2D6. Figure S1 . AUC scores as a function of Tanimoto coefficient cutoff for non-redundant drug sets. Table S2 . Predicted CRDs and NCRDs. 
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